BiotechTube
InSoma Bio

InSoma Bio

San Francisco, United States· Est.
insomabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.8M

Overview

InSoma Bio is a private, preclinical-stage biotech founded in 2019, leveraging a proprietary biomaterials platform to create next-generation solutions for tissue reconstruction. The company's 'Fractomer Biomatrix' is an injectable, thermally-activated material produced via recombinant protein engineering, aiming to improve outcomes in autologous tissue reconstruction. With a founding team combining deep academic expertise in biomedical engineering from Duke University and clinical leadership in plastic surgery, the company is positioned to address significant unmet needs in the reconstructive surgery market. Recent activities include participation in the MedTech Innovator 2025 program and strategic board appointments.

Reconstructive Plastic SurgeryBreast ReconstructionFacial Reconstruction

Technology Platform

Fractomer Biomatrix: A recombinant protein-based, injectable biomaterial platform with a thermal activation switch. It is designed to provide structural support and biointegration for co-injected autologous cells or tissues in reconstructive procedures.

Funding History

1
Total raised:$3.8M
Seed$3.8M

Opportunities

The large and growing markets for breast reconstruction and facial aesthetics present a multi-billion dollar opportunity.
There is significant clinical demand for alternatives to synthetic implants and temporary fillers that offer more natural, durable, and safer outcomes using a patient's own tissue.
Successful penetration into the breast reconstruction segment could pave the way for expansion into broader aesthetic and reconstructive indications.

Risk Factors

Major risks include the preclinical and clinical failure of the novel biomaterial, a complex and uncertain regulatory pathway with the FDA, and future challenges in achieving surgeon adoption and securing insurance reimbursement.
The company also faces competition from established implant makers and other regenerative medicine startups.

Competitive Landscape

InSoma competes in the regenerative biomaterials space, facing competition from large medical device companies (e.g., Allergan, Mentor) offering traditional implants, companies with acellular dermal matrices (e.g., AlloDerm), and other startups developing advanced hydrogels and scaffolds for soft tissue regeneration. Differentiation hinges on the unique recombinant protein design, thermal-switch property, and focus on enhancing autologous tissue transfer.

More companies in Regenerative Medicine →More companies in United States →